DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for osteogenesis imperfecta type 4 — screening already-approved drugs against its 10-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOsteogenesis imperfecta type 4 maps to a 10-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for osteogenesis imperfecta type 4 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
serpin family F member 1 (SERPINF1) — SERPINF1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2-methoxyethoxydrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9J3Q · 1.9 Å · ligand 2-(2-METHOXYETHOXY)ETHANOL (PG0). Experimental structure, not a prediction.
What the evidence adds up to
Osteogenesis imperfecta type 4 is not directly studied in any of the three abstracts provided. The 2014 review covers the genetic reclassification of osteogenesis imperfecta into types caused by collagen defects and those caused by defects in non-collagenous genes, including types V through XII. Type 4 is not mentioned. The 1997 review discusses general progress in understanding osteogenesis imperfecta at the biochemical and genetic level, and notes that management of basilar impression remains unresolved, but it does not report any specific treatment outcomes or survival data. The 2025 clinical case describes a newborn with type XV osteogenesis imperfecta, a rare recessive form caused by a WNT1 gene mutation, and mentions bisphosphonate therapy and the prospect of targeted drugs, but again does not address type 4.
No abstract provides any quantitative results — no survival rates, response rates, or sample sizes — for any treatment of osteogenesis imperfecta type 4. The 2014 review states that identification of causative defects has prompted investigations into common pathways that could translate to new therapies, but this remains a research direction, not a proven intervention. The 1997 review says progress at the molecular level is encouraging but gives no concrete data. The 2025 case discusses bisphosphonate therapy for type XV, but this is a different subtype with a different genetic cause.
What is missing for osteogenesis imperfecta type 4 specifically: no clinical trial data, no patient stratification by mutation, no funding for mechanism-specific therapies, and no evidence that any drug alters the natural history of this subtype. The abstracts collectively show that osteogenesis imperfecta is genetically heterogeneous, but they do not provide evidence for any repurposed drug in type 4.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Pediatrics · 2014 · 139 citations · open access
Osteogenesis imperfecta due to mutations in non-collagenous genes
AbstractPURPOSE OF REVIEW: Osteogenesis imperfecta or 'brittle bone disease' has mainly been considered a bone disorder caused by collagen mutations. Within the last decade, however, a surge of genetic discoveries has created a new paradigm for osteogenesis imperfecta as a collagen-related disorder, where most cases are due to autosomal dominant type I collagen defects, while rare, mostly recessive, forms are due to defects in genes whose protein products interact with collagen protein. This review is both timely and relevant in outlining the genesis, development, and future of this paradigm shift in the understanding of osteogenesis imperfecta. RECENT FINDINGS: Bone-restricted interferon-induced transmembrane (IFITM)-like protein (BRIL) and pigment epithelium-derived factor (PEDF) defects cause types V and VI osteogenesis imperfecta via defective bone mineralization, while defects in cartilage-associated protein (CRTAP), prolyl 3-hydroxylase 1 (P3H1), and cyclophilin B (CYPB) cause types VII-IX osteogenesis imperfecta via defective collagen post-translational modification. Heat shock protein 47 (HSP47) and FK506-binding protein-65 (FKBP65) defects cause types X and XI osteogenesis imperfecta via aberrant collagen crosslinking, folding, and chaperoning, while defects in SP7 transcription factor, wingless-type MMTV integration site family member 1 (WNT1), trimeric intracellular cation channel type b (TRIC-B), and old astrocyte specifically induced substance (OASIS) disrupt osteoblast development. Finally, absence of the type I collagen C-propeptidase bone morphogenetic protein 1 (BMP1) causes type XII osteogenesis imperfecta due to altered collagen maturation/processing. SUMMARY: Identification of these multiple causative defects has provided crucial information for accurate genetic counseling, inspired a recently proposed functional grouping of osteogenesis imperfecta types by shared mechanism to simplify current nosology, and has prodded investigations into common pathways in osteogenesis imperfecta. Such investigations could yield critical information on cellular and bone tissue mechanisms and translate to new mechanistic insight into clinical therapies for patients.
Current Opinion in Pediatrics · 1997 · 20 citations
Osteogenesis imperfecta
AbstractIn the past 20 years, tremendous strides have been made in our understanding of the biochemical and genetic abnormalities associated with osteogenesis imperfecta (OI). Prenatal diagnostic techniques have allowed early detection of this disorder, particularly in families in which the actual molecular defect is already known. Although medical and surgical management of patients with OI continue to improve, the proper management of such problems as basilar impression still need to be determined. Progress in the treatment of OI at a molecular level is encouraging.
Traumatology and Orthopаedics of Kazakhstan · 2025 · 0 citations · open access
Osteogenesis imperfecta type XV: A clinical case
AbstractThe article presents a clinical case of a rare form of osteogenesis imperfecta (type XV) identified in a newborn girl. The key clinical manifestations, genetic aspects of the disease and approaches to diagnostics are described. The results of laboratory and instrumental studies confirming the diagnosis are presented. Therapeutic strategies, including bisphosphonate therapy and the prospects for targeted drug use, are discussed. The work emphasizes the importance of early diagnosis and a multidisciplinary approach to optimize the treatment of patients with this condition.Keywords: osteogenesis imperfecta type XV, rare genetic disorders, WNT1 gene mutation, bisphosphonate therapy, targeted therapy.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
